HRTS
Tema Heart & Health ETF
HRTS seeks to provide investors with exposure to companies that are focused on developing treatments and solutions for obesity and cardiometabolic conditions.
US
EQUITY
Active
MANAGEMENT STYLE
$ 49.4 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Inception date | Nov 20, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 9.5 % |
| UNITEDHEALTH GROUP INC | 5.0 % |
| ROCHE HOLDINGS LTD-SPONS ADR | 4.9 % |
| JOHNSON & JOHNSON | 4.2 % |
| ASTRAZENECA PLC | 4.2 % |
| MERCK & CO. INC. | 4.1 % |
| THERMO FISHER SCIENTIFIC INC | 3.9 % |
| NOVO NORDISK A/S-B | 3.9 % |
| GILEAD SCIENCES INC | 3.4 % |
| NOVARTIS AG | 3.3 % |
Constituent Breakdown
| Number of holdings | 42 |
| Herfindahl-Hirschman Index | 361 |
| Wgt avg mkt cap (mns) | $254,048 |
| Large cap (>$10bn) | 92.0% |
| Mid cap ($2-10bn) | 6.5% |
| Small cap (<$2bn) | 0.3% |
| Developed mkts. | 98.1% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 75.6 % |
 |
SWITZERLAND | 8.2 % |
 |
DENMARK | 5.2 % |
 |
BRITAIN | 4.2 % |
 |
IRELAND | 2.2 % |
 |
ISRAEL | 1.8 % |
 |
JAPAN | 1.5 % |
Historical Performance
Standardized Performance (as of 03/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -4.5% | 14.8% | -0.7% | -- | -- | -- | -- | 10.5% |
| Dividend Yield | 0.0% | 1.6% | 1.4% | -- | -- | -- | -- | 1.3% |
| Total Returns | -4.5% | 16.4% | 0.7% | -- | -- | -- | -- | 11.8% | Ann. Volatility | 17.0% | 19.3% | 18.9% | -- | -- | -- | -- | 19.3% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.59 | 35% |
| MSCI EAFE | 0.72 | 44% |
| MSCI Emg Mkts | 0.50 | 28% |
Liquidity Measures
| Avg. volume (000) | 4 |
| ADV traded (mns) | $0 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.30% |
Technical Indicators
| 30d moving avg. (EMA) | $34.04 |
| Relative strength (RSI) | 44 |
| MACD/Signal | -0.06/-0.04 |
| Bollinger Bands (Upper/Lower) | $34.96/$32.79 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HRTS |
Expenses vs. HRTS |
ALTAR Score™ vs. HRTS |
|---|---|---|---|---|
| IXJ | iShares Global Healthcare ETF | 54.9% | -33 bp | +3.7% |
| XLV | Health Care Select Sector SPDR | 53.9% | -67 bp | +4.0% |
| IYH | iShares U.S. Healthcare ETF | 53.3% | -35 bp | +3.2% |
| FHLC | Fidelity MSCI Health Care Index ETF | 52.9% | -67 bp | +2.6% |
| VHT | Vanguard Health Care ETF | 52.8% | -66 bp | +2.4% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 41.0% | 0 bp | -1.9% |
| HART | IQ Healthy Hearts ETF | 39.1% | -30 bp | +2.7% |
| CANC | Tema Oncology ETF | 35.9% | 0 bp | -5.4% |
| BMED | Future Health ETF | 34.9% | +10 bp | -2.4% |
| JDOC | JPMorgan Healthcare Leaders ETF | 33.9% | -10 bp | +0.7% |
Risk and Returns: HRTS vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/29/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
3.4%
ALTAR SCORE™
15th
PERCENTILE
AVOID
ETFRC RATING
There are 1,201 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. HRTS's ALTAR Score™ is approximately -1.0 standard
deviations above the category average. This places HRTS in the 15th percentile
among funds in the category.
Sell-Side Consensus
$41.57
PRICE TARGET
+25.4%
UPSIDE